Recruiting studies: Tas 102

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Phase 1/Phase 2 · 1 location(s) · National Health Research Institutes, Taiwan · NCT05927857 Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · University of Wisconsin, Madison · NCT05854498 Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomi
Phase 3 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT06850090 Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Re
NA · 1 location(s) · Charite University, Berlin, Germany · NCT05991102 Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal C
Phase 2 · 1 location(s) · Fudan University · NCT06856187 Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Phase 2 · 9 location(s) · Rutgers, The State University of New Jersey · NCT05806931 Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Phase 2 · 2 location(s) · Ruijin Hospital · NCT07085169 Second-line Treatment of Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06242067 Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Phase 1/Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06202001 TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced
Phase 1/Phase 2 · 27 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07044908 TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06293014 TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adj
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05343013 Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
Phase N/A · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06102785 A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/
Phase 2 · 9 location(s) · Criterium, Inc. · NCT06992258 A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of C
Phase 3 · 32 location(s) · AbbVie · NCT07525206 Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05965531 Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Phase 2 · 1 location(s) · LIN YANG · NCT06711471

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.